TMX 049

Drug Profile

TMX 049

Alternative Names: TMX-049

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teijin Pharma
  • Class Antigouts; Uricosurics
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperuricaemia

Most Recent Events

  • 01 Apr 2017 Phase-II clinical trials in Hyperuricaemia in Japan (PO) (JapicCTI173577)
  • 01 Dec 2016 Phase-I clinical trials in Hyperuricaemia (In volunteers) in United Kingdom (PO) (JapicCTI163466)
  • 01 Apr 2015 Phase-I clinical trials in Hyperuricaemia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top